Related Experiment Video
Updated: Mar 9, 2026

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
Published on: May 6, 2014
Severe community-acquired pneumonia: optimal management.
1aInfectious Disease Department, Tor Vergata University Hospital, University of 'La Sapienza', Rome, Italy bClinical Research & Innovation in Pneumonia & Sepsis (CRIPS) cCentro de Investigación Biomédica En Red - Enfermedades Respiratorias (CIBERES), Vall d'Hebron Institute of Research dUniversitat Autònoma de Barcelona, Barcelona, Spain.
Community-acquired pneumonia (CAP) survival is improving due to timely antibiotics and novel diagnostics. Precision medicine and rapid molecular tests offer new hope for reducing CAP mortality.
Area of Science:
- Infectious Diseases
- Pulmonology
- Critical Care Medicine
Background:
- Community-acquired pneumonia (CAP) remains a leading cause of infectious disease mortality.
- Despite advancements, a significant proportion of patients with CAP continue to experience fatal outcomes.
- This review explores recent research to identify new prognostic factors and diagnostic approaches for CAP management.
Purpose of the Study:
- To review the latest research on prognostic factors and diagnostics in community-acquired pneumonia (CAP).
- To identify new perspectives for optimizing the management of CAP.
- To discuss advancements that could potentially reduce CAP-related mortality.
Main Methods:
- Review of recent scientific literature on CAP.
- Analysis of novel biomarkers for predicting severe CAP.
- Evaluation of new molecular diagnostic techniques and omics approaches (metabolomics, genomics, microbiomics).
Main Results:
- CAP survival has improved, despite increased severe cases, with early and appropriate antibiotic therapy being crucial.
- Novel biomarkers (e.g., monocyte human leukocyte antigen-DR, presepsin) and omics technologies show promise in predicting severe CAP and outcomes.
- Rapid molecular tests enhance pathogen detection, revealing high viral prevalence and aiding bacterial identification.
Conclusions:
- Precision medicine for risk stratification and diagnosis is key to optimizing CAP management.
- Rapid molecular testing improves diagnostic yield and guides treatment decisions.
- Integrating these advancements holds potential for further reducing CAP mortality rates.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia III: Complications and Assessment
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
